Sabra Healthcare REIT financials
$19.78−0.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $774.6M | $703.2M | $647.5M | $624.8M | $569.5M | $598.6M | $661.7M | $623.4M | $408.3M | $260.5M |
| Gross profit | $774.6M | $703.2M | $647.5M | $624.8M | $569.5M | $598.6M | $661.7M | $623.4M | $408.3M | $260.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $256.5M | $238.6M | $207.2M | $140.7M | $201.3M | $251.7M | $217.8M | $304.9M | $225.7M | $144.0M |
| Net income | $155.6M | $126.7M | $13.8M | -$77.6M | -$113.3M | $138.4M | $69.0M | $269.3M | $148.1M | $60.0M |
| Net margin | 20.1% | 18.0% | 2.1% | −12.4% | −19.9% | 23.1% | 10.4% | 43.2% | 36.3% | 23.0% |
| Diluted EPS | $0.64 | $0.54 | $0.06 | $-0.34 | $-0.52 | $0.67 | $0.37 | $1.51 | $1.40 | $0.92 |
| EBITDA | $450.9M | $426.7M | $404.6M | $422.5M | $389.7M | $432.4M | $521.1M | $497.7M | $340.9M | $242.3M |
| Operating cash flow | $348.6M | $310.5M | $300.6M | $321.0M | $359.3M | $354.9M | $372.5M | $360.6M | $135.8M | $175.9M |
| Free cash flow | $307.1M | $255.8M | $215.7M | $266.5M | $316.7M | $214.6M | $295.9M | $71.4M | -$291.1M | $21.3M |
| Diluted shares | 244.5M | 236.0M | 232.8M | 230.9M | 219.1M | 207.3M | 188.1M | 178.7M | 105.8M | 65.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.5M | $60.5M | $41.3M | $49.3M | $112.0M | $59.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $2.53B | $2.42B | $2.41B | $2.51B | $2.44B | $2.43B |
| Total assets | $5.49B | $5.30B | $5.39B | $5.75B | $5.97B | $5.99B |
| Total liabilities | $2.67B | $2.56B | $2.58B | $1.24B | $2.59B | $2.58B |
| Shareholders' equity | $2.82B | $2.74B | $2.80B | $4.51B | $3.38B | $3.41B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology